Novartis.com | Contact Us | Help | Site Map | Large Text VersionRegular Text Version

Welcome to Novartis Oncology - The Global Site

 

 

 

Cancer Resources by Novartis Oncology

Disease Awareness

About_Cushings

Cushing's disease is a serious, often undiagnosed health condition that affects men, women, and children around the
world.1-4 The purpose of this website is to provide information that will help increase awareness and understanding of Cushing's disease in the hope that more people with this condition will be diagnosed.

Visit aboutcushings.com

 


Exploring_MPN

Myelofibrosis (MF) is a potentially fatal, clonal myeloproliferative neoplasm. There remains a large unmet need for therapies that address the disease manifestations of myelofibrosis and that can alter the natural course of the disease. Intense research is underway to evaluate novel therapies that target key pathophysiological processes of this MPN subtype.5-7

Click here to visit exploringmpn.com

 


Rare_like_me

Rare diseases are illnesses that affect less than one-tenth of one percent of the population, but are life-threatening or highly disabling.

The purpose of this website is to provide patients and family members with information on three rare diseases:

  • Dermatofibrosarcoma protuberans (DFSP)
  • Hypereosinophilic syndrome (HES)/ Chronic Eosinophilic Leukaemia (CEL)
  • Myelodysplastic/myeloproliferative disorders

Learn more at rarelikeme.com

 


Ribbon_pink

After speaking with breast cancer survivors and health professionals, we learned that there is a real need for information on the subject of life after the initial treatment of breast cancer. And now that more women are living longer after breast cancer than ever before, the need is even greater. Ribbonofpink.com was developed to help fill this need.

Click here for more information at ribbonofpink.com

 


References: 1. Newell-Price J, Bertagna X, Grossman AB, Nieman LK. Cushing's syndrome. Lancet. 2006;367:1605-1617. 2. Nieman LK, Biller BMK, Findling JW, et al. The diagnosis of Cushing's syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2008;93:1526-1540. 3. Boscaro M, Barzon L, Fallo F, Sonino N. Cushing's syndrome. Lancet. 2001;357:783-791. 4. Arnaldi G, Angeli A, Atkinson AB, et al. Diagnosis and complications of Cushing's syndrome: a consensus statement. J Clin Endocrinol Metab. 2003;88:5593-5602. 5. Ghoreschi K, Laurence A, O'Shea JJ. Janus kinases in immune cell signaling. Immunol Rev. 2009;228(1):273-287. 6. Mesa RA. New drugs for the treatment of myelofibrosis. Curr Hematol Malig Rep. 2010;5(1):15-21. 7. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology™: myelodysplastic syndromes. 2010;V.2:1-35.
 

ABOUT NOVARTIS ONCOLOGY

Learn More About Novartis Oncology

We deliver a broad range of innovative therapies, cancer resources and oncology drugs to improve and extend the lives of cancer patients.

PRODUCTS

At Novartis Oncology, we strive to provide a broad range of innovative, practical solutions and authoritative resource therapies.

WHAT IS CANCER?

Knowing more about different diseases and conditions will make it easier to keep you and your family healthy.